EchoGo Amyloidosis vs EchoGo Core
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 70/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
EchoGo Amyloidosis is a specialized AI-powered screening tool designed specifically for the early detection of cardiac amyloidosis, providing a 'suggestive' or 'not suggestive' output. In contrast, EchoGo Core is a general-purpose AI platform that automates standard echocardiogram analysis to provide precise measurements for confident cardiac diagnosis, such as LV ejection fraction and volumes. While both leverage AI for echocardiogram analysis within cardiology, EchoGo Amyloidosis targets a specific disease, whereas EchoGo Core focuses on broader automation of routine measurements.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Amyloidosis is an AI-powered screening tool specifically designed to aid in the early detection of cardiac amyloidosis by analyzing echocardiogram video clips. In contrast, EchoGo Core is an AI-powered platform that automates general echocardiogram analysis, providing precise measurements for confident cardiac diagnosis and improved patient outcomes, including automated LV analysis (EF, GLS, LV volumes).
EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis based on its analysis of echocardiographic markers like ventricular volume, cardiac function, and myocardial movement. EchoGo Core, on the other hand, automates the calculation of specific measurements such as Left Ventricular Ejection Fraction (EF), Global Longitudinal Strain (GLS), and Left Ventricular volumes (LV EDV, LV ESV).
Both tools are designed for seamless integration. EchoGo Amyloidosis integrates with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7. EchoGo Core offers vendor-neutral integration with existing PACS/EHR systems and supports structured reporting.
EchoGo Amyloidosis boasts high diagnostic accuracy for cardiac amyloidosis, with 85% sensitivity and 93% specificity, and consistent performance across CA subtypes. EchoGo Core emphasizes zero inter- and intra-variability in its automated measurements, ensuring accuracy and reproducibility across over 230 measurements.
EchoGo Amyloidosis is primarily designed for Cardiology. EchoGo Core is intended for a broader range of specialties, including Cardiology, Critical Care, and Emergency Medicine.